Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Biodexa Pharmaceuticals Plc made materially false and/or misleading statements and/or failed to disclose that: On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma. Biodexa disclosed that of the four patients who were enrolled in Cohort A of the study, two are now deceased, with one achieving an overall survival of 12 months and the other 13 months since the start of treatment. Follow this news, Biodexa's stock price fell over 7% on the same day.
In order to be eligible to join the BDRX class action lawsuit, you must have incurred a loss on shares of Biodexa Pharmaceuticals Plc purchased during the class period listed above.
TOP
